Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Rating of “Moderate Buy” from Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $18.3333.

Several research firms have commented on CADL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Candel Therapeutics in a report on Monday, September 29th. Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Stephens restated an “overweight” rating and issued a $15.00 price target on shares of Candel Therapeutics in a research report on Monday, December 8th. Finally, Citigroup cut their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, November 14th.

Candel Therapeutics Price Performance

CADL stock opened at $6.01 on Tuesday. The stock has a market cap of $329.95 million, a price-to-earnings ratio of -10.54 and a beta of -0.93. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The company has a 50 day simple moving average of $5.54 and a 200 day simple moving average of $5.63. Candel Therapeutics has a 1 year low of $4.25 and a 1 year high of $13.68.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Research analysts anticipate that Candel Therapeutics will post -1.47 EPS for the current fiscal year.

Institutional Trading of Candel Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its holdings in Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after acquiring an additional 7,527 shares during the period. Invesco Ltd. bought a new position in shares of Candel Therapeutics in the 1st quarter worth about $59,000. Taylor Financial Group Inc. lifted its stake in shares of Candel Therapeutics by 36.0% in the 3rd quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company’s stock valued at $69,000 after purchasing an additional 3,600 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Candel Therapeutics in the 2nd quarter valued at about $70,000. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.